Blog

The recurring problem in healthtech around defining Annual Recurring Revenue (ARR) stems from the complexities of the healthcare revenue cycle and the diversity of business models, which often go beyond the simple subscription model of traditional SaaS.While the general definition of ARR is the predictable, recurring revenue a company expects to receive annually from its customers, healthtech companies face specific challenges:1. Hybrid Business Models Many healthtech companies are not pure Software-as-a-Service (SaaS). They are often Tech-Enabled Services or a hybrid, where recurring revenue is tied to:&nbsp; Usage or Consumption: Revenue based on the volume of transactions, claims processed, or per-patient engagement, which can fluctuate and be less predictable than a flat subscription. Capitation/Per Member Per Month (PMPM) Fees: Payments received from payers (insurers) or employers on a per-member basis, which may have variable enrollment or utilization rates. Service Components: Blending software subscriptions with professional services (e.g., clinical support, implementation, data analytics), where only the truly recurring software/platform fee should be counted as ARR. The Problem: Distinguishing between truly recurring revenue (ARR) and variable or one-time service revenue can be difficult. Misclassifying these can artificially inflate the ARR figure, misleading investors about the company's financial health and predictability.2. Implementation and One-Time Fees Healthtech deals, especially with large hospital systems or payers, often include significant one-time fees for:Implementation/Integration: Connecting the tech solution to Electronic Health Records (EHRs) and other legacy systems. Customisation: Tailoring the platform to specific clinical or administrative workflows.The Problem: These one-time fees can be large and make up a significant portion of the initial contract value. Including them in ARR is a common mistake, as they do not recur annually. ARR must strictly exclude these non-recurring charges.3. Long Sales Cycles and Contract Lag Healthcare sales cycles are notoriously long, and contracts often include phased rollouts or terms that delay the start of paid subscription usage.The Problem: There can be a significant lag between signing a contract and the revenue "going live." This creates a distinction between:Committed ARR (CARR): The total value of recurring revenue that has been contractually signed but not yet fully realized or live. Realised ARR: The revenue that is currently being collected based on active users or members.&nbsp; &nbsp; For accurate forecasting and reporting, companies must clearly delineate between these two, as investors prioritise the predictable, realized revenue stream.4. Regulatory and Payment Complexity Unlike generic SaaS, healthtech revenue is highly dependent on complex regulations (like HIPAA) and the intricate healthcare payment landscape (payers, providers, patients).The Problem: Revenue can be subject to:Prior Authorizations and Denials: Technology that helps with the revenue cycle (RCM) may have a recurring fee tied to success metrics, which are influenced by external denial rates.Reimbursement Changes: New billing codes or payer policies can instantly impact the value of a tech solution, making the "annual" value of the recurring fee less stable.In short, the problem is defining a clear, clean, and consistent metric for predictable annual revenue when the core business models and revenue streams are inherently complex, service-heavy, and influenced by external regulatory and payment factors unique to the healthcare industry.To discuss how Nelson Advisors can help your HealthTech, MedTech or Digital Health company, please email <a data-mce-href="mailto:lloyd@nelsonadvisors.co.uk" href="mailto:lloyd@nelsonadvisors.co.uk" title="lloyd@nelsonadvisors.co.uk" target="_blank" rel="noopener">lloyd@nelsonadvisors.co.uk</a>

HealthTech's Recurring Problem: How to define Annually Recurring Revenue

Professional handshake signifying agreement between business professionals during an office meeting focused on collaboration and teamwork

For healthtech founders, understanding the bridge from Enterprise Value (EV) to Equity Value is critical for M&amp;A. While a buyer's offer is typically based on a company's EV, the value of its operating business, the actual cash you receive as a founder is based on its Equity Value. The bridge is a simple calculation that adjusts the EV for your company's balance sheet to determine the final payment to shareholders.The Core Formula 💰 The foundational formula for the EV-to-Equity Value bridge is:Equity Value = Enterprise Value - Net Debt + Other AdjustmentsLet's break down the key components:Enterprise Value (EV): This is the headline number in an M&amp;A offer. It represents the value of your company's core operations, independent of how it's financed. It's what the buyer is paying for your business itself. In healthtech, EV is often calculated using a multiple of your revenue or EBITDA (e.g., EV = Revenue x 5x). Equity Value: This is the final value attributable to shareholders. It is the amount of cash you, your co-founders, and investors will receive at closing. &nbsp; &nbsp;The Bridge: A Closer Look 🌉 The difference between EV and Equity Value is a function of a company's balance sheet. The buyer typically wants to acquire your operating business "cash-free, debt-free," meaning they aren't paying for your cash on hand and won't be inheriting your debt.Net Debt: This is the most significant adjustment. It represents your company's total debt minus its cash and cash equivalents.Formula: Net Debt = Total Debt - Cash &amp; Cash Equivalents Impact: Any debt on your balance sheet will reduce the final Equity Value. Conversely, any cash on hand will increase it, as it's typically distributed to shareholders. Healthtech Context: Be sure to include all debt-like items, which might be less obvious in a tech company, such as capital leases, unfunded pension liabilities, or deferred revenue that is treated as a liability in the deal structure. Other Adjustments: In a real-world M&amp;A deal, other balance sheet items can impact the final price. These are often negotiated and will depend on the deal's specific terms.Preferred Stock: Any value owed to preferred stockholders (e.g., from a Series A or B round) is subtracted from the EV. The proceeds from the sale are distributed according to a pre-defined waterfall, with preferred shareholders often getting paid before common shareholders. Working Capital Adjustments: Buyers will often set a target for a company's working capital (current assets minus current liabilities). If your working capital at closing is below the target, the purchase price may be reduced. If it's above, it may be increased. Transaction Costs: Legal, investment banking, and accounting fees related to the deal are typically paid out of the proceeds, reducing the final amount distributed to shareholders. &nbsp; An Example for a Healthtech Startup 🏥 Let's imagine your digital health company, "HealthMetrics," has received an offer.Proposed Enterprise Value (EV): $50 million (based on a 5x multiple of your $10M in ARR) Now, let's look at your balance sheet to calculate the final Equity Value.Cash on hand: $3 million Total Debt: $5 million (e.g., a bank loan for equipment) Preferred Stock: $8 million (the liquidation preference for your investors) Working Capital Adjustment: Let's assume a negotiated negative adjustment of $500,000. Transaction Costs: $1.5 million The Bridge Calculation:Start with EV: $50,000,000 Subtract Total Debt: - $5,000,000 Add Cash: + $3,000,000 Subtract Preferred Stock: - $8,000,000 Subtract Working Capital Adjustment: - $500,000 Subtract Transaction Costs: - $1,500,000 Final Equity Value = $33,000,000Key Takeaway: The "cheat sheet" is to remember that the EV is not the cash you'll walk away with. You must account for all financial obligations and adjustments to bridge from the EV to the final Equity Value that is paid out to you and your investors.To discuss how Nelson Advisors can help your HealthTech, MedTech, Health AI or Digital Health company, please email <a data-mce-href="mailto:lloyd@nelsonadvisors.co.uk" href="mailto:lloyd@nelsonadvisors.co.uk" title="lloyd@nelsonadvisors.co.uk" target="_blank" rel="noopener">lloyd@nelsonadvisors.co.uk</a>

Enterprise Value to Equity Value bridge explained for Healthtech Founders

Businessman analyzes the graph of trend market growth in 2025 and plans business growth and profit increase in the year 2025. plan finances of the business

In healthtech M&amp;A in 2025, earn-outs are increasingly common and are being used to bridge valuation gaps between buyers and sellers, mitigate risk, and align incentives. The use of these structures is particularly prevalent for high-growth, early-stage companies and those with unproven or developing technologies, such as AI-driven platforms and digital therapeutics.&nbsp;Key Trends and Structures 🤝 Risk-Sharing Mechanism: Earn-outs are a way for buyers to manage the risk of overpaying for a company with unproven technology or an uncertain future revenue stream. They allow the buyer to pay a lower upfront price and a contingent, future payment if the business hits agreed-upon performance metrics. Contingent on Performance: Payments are tied to specific, measurable milestones. These milestones can be financial, like achieving a certain revenue or adjusted EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization), or non-financial, such as receiving regulatory approval (e.g., FDA clearance), launching a new product, or hitting specific customer acquisition targets. Typical Metrics: While revenue and adjusted EBITDA are standard, healthtech deals often incorporate milestone-driven metrics due to the nature of the industry. This is particularly true for biopharma and diagnostics companies, where a deal might be structured with an initial payment and an earn-out tied to a clinical trial's success, regulatory approval, or a product's commercial launch. Earn-out Period and Percentage: Earn-out periods typically range from one to three years to allow sufficient time for the acquired company to achieve the agreed-upon milestones. The contingent portion of the total deal value can vary widely, but for a seller's business that is already generating revenue, the earn-out may constitute 10-20% of the total purchase price. Market Dynamics in 2025 📈 The healthtech M&amp;A market in 2025 is driven by several factors, which influence the use and structure of earn-outs:AI Integration: Companies with proprietary AI algorithms and scalable platforms are commanding higher valuations, often seeing multiples of 6-8x revenue, above the sector average of 4-6x. Earn-outs are used to justify these premiums by tying a portion of the valuation to the successful commercialization and integration of the AI technology. Regulatory Evolution: As regulatory bodies like the FDA refine their frameworks for digital health tools, clear regulatory pathways boost buyer confidence. However, for companies still navigating this uncertainty, earn-outs are a crucial tool to manage risk, with payments contingent on achieving regulatory milestones. Shift to Value-Based Care: Buyers are increasingly interested in healthtech that delivers measurable cost savings and improved patient outcomes. Companies with platforms enabling this shift (e.g., remote monitoring, population health analytics) attract a premium, and earn-outs are used to ensure the technology delivers on its promised value.To discuss how Nelson Advisors can help your HealthTech, MedTech, Health AI or Digital Health company, please email <a data-mce-href="mailto:lloyd@nelsonadvisors.co.uk" href="mailto:lloyd@nelsonadvisors.co.uk" title="lloyd@nelsonadvisors.co.uk" target="_blank" rel="noopener">lloyd@nelsonadvisors.co.uk</a>

HealthTech M&A Earn Outs: Key Trends, Structures and Market Dynamics in 2025

Nelson Advisors partner Lloyd Price has been invited to judge the MedTech Startup Pitch Awards at MedTech Europe 2025 taking place in Malta, November 12th to 14th 2025.MedTech Malta 2025 &nbsp;&nbsp; The MedTech Malta 2025 event is a three-day summit scheduled to take place from November 12-14, 2025, at the Mediterranean Conference Centre in Valletta, Malta. 🇲🇹 &nbsp; What to Expect at MedTech Malta 2025 &nbsp;&nbsp; The conference is a convergence point for a global audience, including investors, entrepreneurs and healthcare leaders. It aims to foster collaboration and showcase the latest advancements in medical technology. The agenda includes: &nbsp;&nbsp; Panel Discussions &amp; Keynotes: featuring experts from various fields within the MedTech ecosystem. Startup Pitch Competitions: offering a platform for emerging companies to showcase their innovations. Exhibitions: with a focus on cutting-edge technologies. Networking Opportunities: including exclusive forums for CEOs and investors. Cultural Activities &amp; Awards Gala: the event is set against the backdrop of Malta's historic capital, with a cultural tour and the prestigious MedTech World Awards Ceremony. &nbsp;&nbsp; The conference is a CPD-accredited event, providing healthcare professionals with an opportunity for professional development. <a data-mce-href="https://med-tech.world/malta/" href="https://med-tech.world/malta/" title="https://med-tech.world/malta/" target="_blank" rel="noopener">https://med-tech.world/malta/</a> European Venture Capital and Private Equity Funds &nbsp;&nbsp; MedTech Malta 2025 will feature over 250 investors and 300 speakers, with 25% of attendees coming from the UK and Europe including: &nbsp;&nbsp; Ken Nelson: A partner at MedTech Advantage Fund with a focus on digital health.Diana Saraceni: Co-Founder and General Partner at Panakes, a venture capital firm that invests in early-stage life sciences companies, primarily in Europe and the U.S.Rachna Dayal: An executive with experience at Philips, Johnson &amp; Johnson, and in venture capital.Greg Madden: A Managing Partner at SV Health Investors, a private investment firm focused on health.The event is designed to facilitate connections and collaboration among various stakeholders in the MedTech ecosystem, with a focus on discussions about capital formation in MedTech, including strategies for early-stage investments and cross-border growth. The MedTech Malta Startup Pitch The MedTech Malta Startup Pitch is a platform for medical technology startups to showcase their innovative products, services, and solutions to a panel of judges and potential investors. This shall provide a unique opportunity for entrepreneurs to gain exposure, receive feedback, and secure funding for their ventures.&nbsp; &nbsp;&nbsp; The event attracts a diverse audience of industry experts, healthcare professionals, investors, and entrepreneurs from around the world. The competition is highly competitive, and the judges evaluate each pitch based on its novelty, feasibility, market potential, and overall impact on healthcare. Top performers receive recognition, networking opportunities, and valuable support to advance their business. &nbsp;&nbsp; Source: <a data-mce-href="https://med-tech.world/malta/pitch/" href="https://med-tech.world/malta/pitch/" title="https://med-tech.world/malta/pitch/" target="_blank" rel="noopener">https://med-tech.world/malta/pitch/</a>

Nelson Advisors invited to Judge the MedTech Startup Pitch Awards at MedTech Europe 2025

Portrait of two African American healthcare professionals in blue scrubs

A breakthrough year for nurse-led innovation in AI is projected for 2026 due to several key factors converging, including the increasing maturity of AI tools, a critical need for solutions to nurse burnout and staff shortages, and a growing recognition of nurses' unique position as leaders in healthcare technology. Nurses are not just end-users of AI; they are becoming crucial developers and implementers. Their clinical expertise and deep understanding of patient care workflows are essential for creating AI tools that are truly effective, ethical, and safe.&nbsp; Key Drivers of Nurse-Led AI Innovation in 20261. Addressing the Nursing Crisis 🩺 The healthcare industry continues to face a critical nursing shortage and high rates of burnout. By 2026, AI is expected to become a vital part of the solution. AI-powered tools can significantly reduce administrative burdens for nurses, such as automating documentation, charting, and scheduling. This frees up their time to focus on direct patient care, which is the most valuable and rewarding part of their job. Nurse-led innovation in this area ensures that the tools being developed genuinely meet the needs of frontline staff, leading to higher adoption rates and better outcomes.&nbsp; 2. Maturation of AI and EHR Integration 🤖 By 2026, AI technology, particularly large language models (LLMs) and predictive analytics, will have advanced to a point where it can be seamlessly integrated into existing Electronic Health Record (EHR) systems. This is a crucial step for widespread adoption. As major EHR vendors release more sophisticated AI tools, nurses will have a solid foundation to build upon. They can use their clinical knowledge to fine-tune these systems, ensuring the AI provides contextual and clinically relevant recommendations rather than generic, disruptive alerts.3. Nurses as "Digital Health" Leaders 👩‍💻 The role of a nurse is already evolving to include digital health. Nurses are at the forefront of implementing telehealth, remote patient monitoring, and other digital tools. This experience positions them perfectly to lead AI projects. They have a unique perspective on patient needs and the realities of clinical workflows, which is vital for designing user-friendly and effective AI applications. Nursing education programs are also beginning to incorporate training on AI literacy and data science, empowering a new generation of nurses to become innovators and collaborators in technology development.Opportunities and Challenges Opportunities ✨ Enhanced Clinical Decision Support: Nurse-led AI can provide real-time, personalized recommendations for care plans, medication management, and early warning signs of patient deterioration, helping to improve patient safety and outcomes.Personalised Patient Care: AI can analyze patient data to create tailored treatment plans and educational materials, which nurses can then use to empower patients in their own health journey.New Career Paths: The integration of AI will create new roles for nurses in informatics, data science, and AI implementation strategy, offering opportunities for professional growth and leadership.Challenges 🚧 Ethical Concerns: Nurses must be involved in addressing ethical questions, such as algorithmic bias and accountability for AI-driven errors. Their role as patient advocates is crucial to ensuring AI is used equitably.Training and Adoption: Successfully integrating AI requires adequate training for the nursing workforce. Without proper education and support, there may be resistance to adopting new technologies.&nbsp;Data Quality and Interoperability: AI models are only as good as the data they are trained on. Challenges with inconsistent or incomplete data across different healthcare systems could hinder the development of effective AI tools.To discuss how Nelson Advisors can help your HealthTech, MedTech, Health AI or Digital Health company, please email <a data-mce-href="mailto:lloyd@nelsonadvisors.co.uk" href="mailto:lloyd@nelsonadvisors.co.uk" title="lloyd@nelsonadvisors.co.uk" target="_blank" rel="noopener" data-mce-selected="inline-boundary">lloyd@nelsonadvisors.co.uk</a>

2026 predicted to be a breakthrough year for Nurse led Innovation in Healthcare AI

Subconscious vibro-tactile stimulation is a type of sensory input where vibrations are used to influence the body and brain, but the vibrations are either too subtle to be consciously perceived, or their effect is processed by the brain's subconscious systems rather than our conscious awareness. This stimulation is distinct from typical haptic feedback, which is designed to be felt directly and consciously.This method works by engaging the body's somatosensory system, which includes nerves and receptors in the skin and muscles that detect touch, pressure, and vibration. By providing a continuous, low-level stream of this feedback, the brain is given additional information to process, which it can use to improve balance, motor control, or sensory perception without the individual having to actively think about it.Key ApplicationsBalance and Mobility Improvement: This is one of the most significant applications. For individuals with balance disorders like bilateral vestibulopathy (a condition affecting the inner ear's balance organs), a specialised belt with small vibrators can be worn around the waist. These vibrators provide subtle cues about the person's body sway, which the brain's subconscious processes and uses to make micro-adjustments to posture, significantly reducing the risk of falls and improving mobility. Sensory Substitution: The technology can be used to help individuals who have lost one sense to "perceive" the world through another. For example, some devices translate auditory or visual information into patterns of vibration on the skin. Over time, the brain's neuroplasticity allows it to learn to interpret these tactile patterns as if they were a sound or an image, effectively "rewiring" the brain. Rehabilitation and Stroke Recovery: Subconscious vibro-tactile stimulation has been shown to assist in motor recovery for stroke patients. By applying vibrations to a limb, the stimulation can enhance sensory feedback and promote neural reorganization in the brain, helping to reduce spasticity and improve motor function. Stress Reduction and Neurostimulation: Research into vibroacoustic therapy suggests that low-frequency vibrations can influence the autonomic nervous system. This can lead to increased parasympathetic activity, promoting a state of calm and relaxation without conscious effort from the user. There is also emerging research on using vibrotactile stimulation to non-invasively entrain specific brainwave frequencies, such as gamma oscillations, which is being explored as a potential treatment for conditions like Alzheimer's disease.To discuss how Nelson Advisors can help your HealthTech, MedTech, Health AI or Digital Health company, please email <a data-mce-href="mailto:lloyd@nelsonadvisors.co.uk" href="mailto:lloyd@nelsonadvisors.co.uk" title="lloyd@nelsonadvisors.co.uk" target="_blank" rel="noopener" data-mce-selected="inline-boundary">lloyd@nelsonadvisors.co.uk</a>

Nelson Advisors

Blog

HealthTech's Recurring Problem: How to define Annually Re...

Enterprise Value to Equity Value bridge explained for Hea...

HealthTech M&A Earn Outs: Key Trends, Structures and Mark...

Nelson Advisors invited to Judge the MedTech Startup Pitc...

2026 predicted to be a breakthrough year for Nurse led In...

Subconscious vibro-tactile stimulation: HealthTech to wat...